Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.22.4224PMID 11709566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Factors influencing the effect of age on prognosis in breast cancer: population based study

  2000cited by this paper
• The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial. Ontario Clinical Oncology Group.

  2000cited by this paper
• High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.

  2000cited by this paper
• The effects of radiation therapy on quality of life of women with breast carcinoma

  2000cited by this paper
• Short and long‐term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial

  1999cited by this paper
• The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.

  1999cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel.

  1999cited by this paper
• Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS).

  1999cited by this paper
• Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression.

  1998cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.

  1998cited by this paper
• Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

  1998cited by this paper
• The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer.

  1997cited by this paper
• Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.

  1997cited by this paper
• Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review.

  1997cited by this paper
• Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer.

  1997cited by this paper
• A comparative study of post-operative psychosocial function in women with primary operable breast cancer randomized to breast conservation therapy or mastectomy.

  1997cited by this paper
• Quality of life after breast conservation or mastectomy: a systematic review.

  1997cited by this paper
• Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

  1997cited by this paper
• Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

  1996cited by this paper
• Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.

  1996cited by this paper
• Locally advanced breast carcinoma: accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy.

  1996cited by this paper
• Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation.

  1996cited by this paper
• Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.

  1995cited by this paper
• Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

  1995cited by this paper
• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

  1995cited by this paper
• Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach.

  1995cited by this paper
• Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study.

  1994cited by this paper
• Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer.

  1994cited by this paper
• Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.

  1994cited by this paper
• Mammography in the assessment of response to medical treatment of large primary breast cancer.

  1993cited by this paper
• Neoadjuvant chemotherapy in 126 operable breast cancers.

  1992cited by this paper
• The Bigger the Better?

  1991cited by this paper
• Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.

  1991cited by this paper
• Neoadjuvant chemotherapy in operable breast cancer.

  1991cited by this paper
• Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

  1990cited by this paper
• Neoadjuvant Chemotherapy or Chemotherapy and Endocrine Therapy in Locally Advanced Breast Carcinoma: A Prospective, Randomized Study

  1990cited by this paper
• Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice.

  1989cited by this paper
• Presence of a growth-stimulating factor in serum following primary tumor removal in mice.

  1989cited by this paper
• Multimodal treatment of locoregionally advanced breast cancer

  1983cited by this paper
• Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.

  1983cited by this paper
• Toxic effects of early adjuvant chemotherapy for breast cancer.

  1983cited by this paper
• A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

  1979cited by this paper
• Further observations on the inhibition of tumor growth by C. parvum with cyclophosphamide. VII. Effect of treatment prior to primary tumor removal on the growth of distant tumor

  1979cited by this paper
• Effect of surgical removal on the growth and kinetics of residual tumor.

  1979cited by this paper
• A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

  1979cited by this paper
• Assessment of response to therapy in advanced breast cancer.

  1977cited by this paper

• Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.

  2026cites this paper
• Multi-Level Volumetric Transformer for Early Prediction of Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

  2026cites this paper
• Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes in breast cancer patients: a systematic review study

  2025cites this paper
• Impact of Pathologic Complete Response on Local-Regional Recurrence and Survival in Patients Undergoing Neoadjuvant Systemic Therapy and Breast-Conserving Surgery

  2025cites this paper
• Patterns of response of breast cancer after neoadjuvant chemotherapy according to molecular subtype

  2025cites this paper
• Comparative survival outcomes of neoadjuvant and adjuvant therapy in patients with T1c, node-negative, triple-negative breast cancer: A population-based analysis

  2025cites this paper
• Which surgery for breast cancer after neoadjuvant chemotherapy.

  2025cites this paper
• Effect of chemotherapy timing in triple-negative breast cancer: a real-world evidence study

  2025cites this paper
• BJS commission on the surgical management of the axilla in breast cancer

  2025cites this paper
• INFLUENCE OF NEOADJUVANT CHEMOTHERAPY ON THE SIZE AND SPREAD OF THE TUMORAL PROCESS AND INDICATORS OF PROLIFERATIVE ACTIVITY IN BREAST CANCER PATIENTS WHO SUFFERED FROM THE CHRONICLE NUCLEAR POWER PLANT ACCIDENT.

  2025cites this paper
• Performance of sentinel lymph node biopsy after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: systematic review and meta-analysis

  2025cites this paper
• Extending Eligibility for Breast Conserving Therapy: A Review of Emerging Indications and Techniques to Enable Breast Conservation

  2025cites this paper
• Personalized neoadjuvant strategy using 70-gene assay to increase breast-conserving surgery in ER+/HER2– breast cancer

  2025cites this paper
• Subnipple Cyst Formation Is an Important Diagnostic Clue for Mixed-Type Squamous Cell Carcinomas of the Breast: A Case Report

  2025cites this paper
• Predicting the efficacy of neoadjuvant chemotherapy for breast cancer based on dynamic diffuse spectral imaging

  2025cites this paper
• Surgical outcomes of neoadjuvant endocrine treatment in early breast cancer: meta-analysis

  2024cites this paper
• Functional hemodynamic imaging markers for the prediction of pathological outcomes in breast cancer patients treated with neoadjuvant chemotherapy

  2024cites this paper
• Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer

  2024cites this paper
• Predictors of mastectomy in breast cancer patients with complete remission of primary tumor after neoadjuvant therapy: A retrospective study.

  2024cites this paper
• Breast surgery after neoadjuvant systemic therapy

  2024cites this paper
• Elasticity Values as a Predictive Modality for Response to Neoadjuvant Chemotherapy in Breast Cancer

  2024cites this paper
• Discovery of a proliferation essential gene signature and actin‐like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple‐positive breast cancer

  2024cites this paper
• Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival

  2024cites this paper
• De-Escalation Surgery in cT3-4 Breast Cancer Patients after Neoadjuvant Therapy: Predictors of Breast Conservation and Comparison of Long-Term Oncological Outcomes with Mastectomy

  2024cites this paper
• Does Neoadjuvant Chemotherapy in Clinical T1–T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?

  2024cites this paper
• Longitudinal registration of T1-weighted breast MRI: A registration algorithm (FLIRE) and clinical application

  2024cites this paper
• Survival Outcomes of Breast-Conserving Surgery Versus Mastectomy in Locally Advanced Breast Cancer Following Neoadjuvant Chemotherapy: A Meta-Analysis

  2024cites this paper
• Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database

  2024cites this paper
• Value of digital breast tomosynthesis in characterization of breast lesions in dense breast

  2024cites this paper
• miR-21 Expression and its Correlation with Demographics, Subtypes, and Tumour Suppressor Genes; PTEN and PDCD4 in Breast Cancer Tissues in Malaysia

  2024cites this paper
• The Impact of Neoadjuvant versus Adjuvant Chemotherapy on Survival Outcomes in Locally Advanced Breast Cancer

  2024cites this paper
• Triple-negative breast cancer patients treated with subcutaneous mastectomy with immediate reconstruction: single institution experience

  2024cites this paper
• Develop and Validate a Nomogram Combining Contrast-Enhanced Spectral Mammography Deep Learning with Clinical-Pathological Features to Predict Neoadjuvant Chemotherapy Response in Patients with ER-Positive/HER2-Negative Breast Cancer.

  2024cites this paper
• Identifying subgroups of ypN1 breast cancer patients who may exempt from axillary lymph node dissection after neoadjuvant chemotherapy: insights from a large cohort study

  2024cites this paper
• Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study

  2024influential citation
• Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study.

  2024cites this paper
• Peritumoral Adipose Tissue Features Derived from [18F]fluoro-2-deoxy-2-d-glucose Positron Emission Tomography/Computed Tomography as Predictors for Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

  2024cites this paper
• Prediction of complete response after neoadjuvant chemotherapy for invasive breast cancers: The utility of shear wave elastography and superb microvascular imaging in pretreatment breast ultrasound.

  2024cites this paper
• Collagen Density Is Associated With Pathological Complete Response to Neoadjuvant Chemotherapy in Triple‐Negative Breast Cancer Patients

  2024cites this paper
• Low breast density and peritumoral edema on MR predict worse overall survival of breast cancer patients after neoadjuvant chemotherapy.

  2024cites this paper
• Survival outcomes of neoadjuvant versus adjuvant therapy in patients with T1c, node‐negative, human epidermal growth factor receptor 2–positive breast cancer: A Surveillance, Epidemiology, and End Results population‐based study

  2024cites this paper
• Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression

  2024cites this paper
• The Feasibility and Reliability of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Negative Axillary Lymph Nodes—A Meta-analysis

  2024cites this paper
• Uncovering driver genes in breast cancer through an innovative machine learning mutational analysis method

  2024cites this paper
• A generalized non-linear model predicting efficacy of neoadjuvant therapy in HER2+ breast cancer

  2023cites this paper
• The underused potential of breast conserving therapy after neoadjuvant system treatment – Causes and solutions

  2023cites this paper
• Preoperative considerations and benefits of neoadjuvant chemotherapy: insights from a 12-year review of the Hong Kong Breast Cancer Registry.

  2023cites this paper
• Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.

  2023cites this paper
• Technetium-99-Guided Axillary Lymph Node Identification: A Case Report of a Novel Technique for Targeted Lymph Node Excision Biopsy for Node Positive Breast Cancer After Neoadjuvant Chemotherapy

  2023cites this paper
• Radiofrequency ablation in breast-conserving surgery after neo-adjuvant chemotherapy and analysis of antibacterial effect of Ag nanogel

  2023cites this paper
• Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer

  2023cites this paper
• Single Incision Lateral Mammoplasty as an Oncoplastic Technique in Laterally Located Breast Cancer; a Prospective Controlled Study

  2023cites this paper
• The Role of Ultrasound Features in Predicting the Breast Cancer Response to Neoadjuvant Chemotherapy

  2023cites this paper
• Evaluation of Treatment Response in Patients with Breast Cancer.

  2023cites this paper
• Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy

  2023cites this paper
• Changing the role of pCR in breast cancer treatment - an unjustifiable interpretation of a good prognostic factor as a “factor for a good prognosis“

  2023cites this paper
• Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study

  2023cites this paper
• Post-mastectomy Radiation Therapy in HER-2 Positive Breast Cancer after Primary Systemic Therapy: Pooled Analysis of TRYPHAENA and NeoSphere Trials.

  2023cites this paper
• Predicting Pathological Complete Response in Breast Cancer After Two Cycles of Neoadjuvant Chemotherapy by Tumor Reduction Rate: A Retrospective Case-Control Study

  2023cites this paper
• Outcomes of a Multidisciplinary Team in the Management of Patients with Early-Stage Breast Cancer Undergoing Neoadjuvant Chemotherapy at a Community Cancer Center

  2023cites this paper
• Prognostic analysis of three forms of Ki‐67 in patients with breast cancer with non‐pathological complete response before and after neoadjuvant systemic treatment

  2023cites this paper
• Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases

  2023cites this paper
• The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience

  2023cites this paper
• To Ablate or Not to Ablate: Does Umbilectomy Decrease Donor-Site Complications in DIEP Flap Breast Reconstruction?

  2023cites this paper
• De-Escalating Breast Cancer Therapy.

  2023cites this paper
• Anti-Tumor Immunity and Preoperative Radiovaccination: Emerging New Concepts in the Treatment of Breast Cancer

  2023cites this paper
• The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data

  2023cites this paper
• Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions

  2023cites this paper
• Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment

  2023cites this paper
• Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.

  2022cites this paper
• Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer

  2022cites this paper
• The History of Early Breast Cancer Treatment

  2022cites this paper
• What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?

  2022cites this paper
• The Radiological Response Rate Pattern Is Associated With Recurrence Free Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

  2022cites this paper
• Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy.

  2022cites this paper
• Abbreviated and Standard Breast MRI in Neoadjuvant Chemotherapy Response Evaluation: A Comparative Study.

  2022cites this paper
• Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference

  2022cites this paper
• An Integrative Clinical Model for the Prediction of Pathological Complete Response in Patients with Operable Stage II and Stage III Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

  2022cites this paper
• Prospective Evaluation of Response Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

  2022cites this paper
• Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC

  2022cites this paper
• Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends

  2022cites this paper
• Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes

  2022cites this paper
• Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer

  2022cites this paper
• A Novel Machine Learning Method for Mutational Analysis to Identifying Driver Genes in Breast Cancer

  2022cites this paper
• Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study

  2022cites this paper
• Survival After Breast-Conserving Surgery Compared with that After Mastectomy in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

  2022cites this paper
• Clinical Trials in Breast Cancer: Practice Changing, Landmark with a Focus on More Current Trials.

  2022cites this paper
• Evaluating the Fragility of Long-Term Outcomes for Neoadjuvant versus Adjuvant Chemotherapy Prescription in Early Breast Cancer: Pooled Data from 10 Randomised Clinical Trials

  2022cites this paper
• Prognostic Role of Tumor Size Reduction >50% after Neoadjuvant Chemotherapy for Breast Cancer

  2022cites this paper
• Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study

  2022cites this paper
• Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study

  2022cites this paper
• Early assessment of shear wave elastography parameters foresees the response to neoadjuvant chemotherapy in patients with invasive breast cancer

  2021cites this paper
• Neo-Adjuvant Chemotherapy in Luminal, Node Positive Breast Cancer: Characteristics, Treatment and Oncological Outcomes: A Single Center's Experience.

  2021cites this paper
• Surgical Management of the Breast and Axilla after Neoadjuvant Therapy.

  2021influential citation
• Oncological Safety of Oncoplastic Level II Mammoplasties After Neoadjuvant Chemotherapy for Large Breast Cancers: A Matched-Cohort Analysis

  2021cites this paper
• Despite Equivalent Outcomes, Men Receive Neoadjuvant Chemotherapy Less Often Than Women for Lymph Node-Positive Breast Cancer

  2021cites this paper
• Unplanned breast‐conserving surgery after systemic therapy in locally advanced breast cancer: The results of level II oncoplastic techniques

  2021cites this paper
• Despite Equivalent Outcomes, Men Receive Neoadjuvant Chemotherapy Less Often Than Women for Lymph Node-Positive Breast Cancer

  2021cites this paper
• Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment

  2021cites this paper
• Identi cation of a 10-Gene Signature Model to Predict E cacy of Neoadjuvant Therapy in Patients With HER2 Positive Breast Cancer

  2021cites this paper